Local and systhemic immunotherapy for bladder cancer: from bench to bedside

被引:0
|
作者
Carballido, Joaquin A. [1 ]
Vazquez Alba, David [1 ]
Rodriguez Monsalve, Maria [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Serv & Catedra Urol, Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2020年 / 73卷 / 10期
关键词
Transitional cell bladder carcinom; Immunology and bladder cancer; Immunotherapy; Bacillus Calmette-Guerin; BCG Mechanism of action; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; T1 PAPILLARY CARCINOMA; TUMOR-NECROSIS-FACTOR; HIGH-RISK TA; INTRAVESICAL BCG; UROTHELIAL CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic approaches for treatment of urothelial transitional cell carcinoma based on immune system modulation, as well as the contribution of introvesical Bacillus de Calmette-Guerin (BCG) and the recent incorporation of checkpoint inhibitors had found irrefutable proofs of concept for the indication of antitumoral immunontherapy in such tumors. Its extension and development at the present time covers all the locations of the wide spectrum of presentation and evolution of these tumors. Nowadays, apart for the low grade non muscle-invasive tumors, we are facing an unpredictable development of antitumoral immunotherapy in bladder cancer not only as an option in the primary treatment, but also in other scenarios such as non-responders when it comes to BCG, or the situation of ineligibility for systemic chemotherapy indication. The main objective of this review article is trying to translate the current basic mechanisms involved in different phases of transitional cell carcinomas antitumoral response, regardless of whether they are muscle-invasive or not, and to establish the rationale for their therapeutic intravesical or systemic administration. The role of the interactions established between urothelial tumor cells and the cellular and molecular elements of the immune system of patients is described, incorporating the relevant and recent advances in immunobiology and the molecular characterization of these tumors that will undoubtedly introduce far-reaching modifications in therapeutic regimes that will contrast with the traditional options available. Investigational lines that are already active in the clinical research phase with BCG and, checkpoints inhibitors of the immune response are also analyzed, highlighting the need to find predictive response markers as a real option for treatments personalization. The approach to the knowledge of the individual reactivity of the immune system of each patient as a determining factor to achieve it is proposed.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 50 条
  • [11] From bench to bedside: Single-cell analysis for cancer immunotherapy
    Davis-Marcisak, Emily F.
    Deshpande, Atul
    Stein-O'Brien, Genevieve L.
    Ho, Won J.
    Laheru, Daniel
    Jaffee, Elizabeth M.
    Fertig, Elana J.
    Kagohara, Luciane T.
    CANCER CELL, 2021, 39 (08) : 1062 - 1080
  • [12] CAR-NK cells for cancer immunotherapy: from bench to bedside
    Leisheng Zhang
    Yuan Meng
    Xiaoming Feng
    Zhongchao Han
    Biomarker Research, 10
  • [13] Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy
    Napoletano, Chiara
    Bellati, Filippo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [14] Path towards mRNA delivery for cancer immunotherapy from bench to bedside
    Chen, Wenfei
    Zhu, Yining
    He, Jinhan
    Sun, Xun
    THERANOSTICS, 2024, 14 (01): : 96 - 115
  • [15] CAR-NK cells for cancer immunotherapy: from bench to bedside
    Zhang, Leisheng
    Meng, Yuan
    Feng, Xiaoming
    Han, Zhongchao
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [16] From Bench to Bedside: Bringing Immunotherapy Into the Clinic
    Finkelstein, Steven Eric
    CANCER CONTROL, 2013, 20 (01) : 4 - 5
  • [17] THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside
    Moretti, Sonia
    Menicali, Elisa
    Nucci, Nicole
    Guzzetti, Martina
    Morelli, Silvia
    Puxeddu, Efisio
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 183 (02) : R41 - R55
  • [18] Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside
    Arafar, Arashar
    BIOMEDICAL RESEARCH AND THERAPY, 2014, 1 (02): : 71 - 77
  • [19] CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
    Zhu, Xingwang
    Xue, Jieyun
    Jiang, Hongzhou
    Xue, Dongwei
    MOLECULAR CANCER, 2024, 23 (01)
  • [20] Immunotherapy for invasive fungal infections: from bench to bedside
    Pappas, PG
    DRUG RESISTANCE UPDATES, 2004, 7 (01) : 3 - 10